Sector News

Mallinckrodt amps up hospital business with $1.3B Therakos buy

August 11, 2015
Life sciences
Mallinckrodt has made its second buy of the year–and the company believes it’s the perfect match for its first purchase.
 
The Irish drugmaker agreed to fork over about $1.33 billion to investment firm The Gores Group for immunotherapy maker Therakos in a deal that should bolster its hospital offerings. Therakos specializes in extracorporeal photopheresis, a form of therapy approved to treat symptoms associated with a common form of skin cancer.
 
The acquisition fits “hand-in-glove” with Mallinckrodt’s ($MNK) previous deal–a $2.3 billion purchase of Ikaria that brought it access to a respiratory med for babies in neonatal ICUs, execs said on a conference call, as quoted by Reuters. Mallinckrodt can reach out to medical establishments already using that treatment–dubbed INOmax–to help build demand for Therakos’ devices, which they forecast could haul in $500 million or more per year.
 
The pact may come as no surprise to some industry watchers. Mallinckrodt has been on an M&A spree lately, last year shelling out $5.8 billion for Questcor Pharmaceuticals–and its controversial multiple sclerosis med H.P. Acthar Gel–and inking a pact to lay down $1.6 billion for Cadence Pharmaceuticals just two months before that. And Moody’s, for one, last month predicted the Dublin drugmaker would continue to build up its hospital products business, purchasing companies with injectables or other drugs used in a hospital setting.
 
And Mallinckrodt may not stop there. With a limited internal pipeline in its branded business, the company will “likely continue to make acquisitions in order to drive long-term growth,” the investor service wrote in a recent report. But while competitors like Endo ($ENDP) will be able to look to M&A-related synergies for profit-margin gains, Mallinckrodt will likely need to find its own in internal restructuring and shifts in product mix, the Moody’s report predicted.
 
By Carly Helfand
 

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach